Lymphoma News

The FDA granted priority review to parsaclisib for two lymphoma indications.

Three individuals have been elected to American Society of Hematology’s executive committee.

Expanded use of chimeric antigen receptor T cells for cancer treatment requires that less expensive therapies be developed faster using multiple manufacturing models, according to an FDA official.

The FDA granted priority review to tisagenlecleucel, a chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory follicular lymphoma who received two prior lines of therapy.

The FDA cleared an investigational new drug application for PRGN-3007, a chimeric antigen receptor T-cell therapy for patients with advanced hematologic malignancies or solid tumors that express receptor tyrosine kinase-like orphan receptor 1.

The sense of urgency surrounding the COVID-19 pandemic led to speedy development of several vaccines against the SARS-CoV-2 virus.

Numerous academic medical centers around the world have demonstrated the ability to develop and produce safe and effective chimeric antigen receptor T-cell therapies.

Racial disparities in cancer clinical trial enrollment have existed for decades, with Black, Hispanic and other underserved populations prevented from accessing the same cutting-edge treatments as their white counterparts.

A collaborative team of cancer experts from leading academic institutions and organizations has released recommendations for optimal protection against COVID-19 among individuals with blood cancer.

American Association for Cancer Research urged the CDC to expand availability of COVID-19 booster vaccinations to caregivers and other individuals who share a home with patients with cancer.